Premium
Vildagliptin: alternative add‐on therapy for oral glycaemic control
Author(s) -
Chaplin Steve,
Campbell Ian
Publication year - 2008
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.294
Subject(s) - vildagliptin , medicine , metformin , adverse effect , diabetes mellitus , type 2 diabetes , intensive care medicine , dipeptidyl peptidase 4 , pharmacology , endocrinology
Vildagliptin, an oral DPP‐4 inhibitor, is licensed as an add‐on therapy when adequate glycaemic control has not been achieved with metformin, a sulphonylurea or a glitazone. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Professor Ian Campbell comments on its place in type 2 diabetes therapy. Copyright © 2008 Wiley Interface Ltd
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom